Five-day courses of irinotecan as palliative therapy for patients with neuroblastoma

Title

Five-day courses of irinotecan as palliative therapy for patients with neuroblastoma

Creator

Kushner BH; Kramer K; Modak S; Cheung NK

Identifier

Publisher

Cancer

Date

2005

Subject

U.S. Gov't; PedPal Lit; Non-U.S. Gov't Research Support; 15 patients had stable disease; 2 (n=3); 2 (n=9); 22 (n=1 patient); 3 (n=1); 4 (n=2(TRUNCATED); 4 (n=6); 7 (n=1 patient); 7 were not evaluable for response because of concurrent radiotherapy; Adolescent Adult Antineoplastic Agents; although they did not have progressive disease (PD) after receiving 1 (n=10); and 1 patient had a major response. Twenty-one patients had PD after 1 (n=3; and myelosuppressive effects were readily managed. Hospitalizations were limited to three patients with bacteremia. Twenty-three patients had a change in therapy; diarrheal; Intravenous Male Nervous System Neoplasms/drug therapy Neuroblastoma/drug therapyPalliative Care Quality of Life Research Support; or 24 (n=1) courses. The most common reasons for changing treatment were to intensify retrieval therapy or to pursue immunotherapy. Of those 23 patients; P.H.S. Retrospective Studies Treatment Outcome; Phytogenic/administration & dosage/adverse effects Camptothecin/administration & dosage/adverse effects/analogs & derivatives Child Child; Preschool Female Humans Infusions

Description

2005

Rights

Article information provided for research and reference use only. PedPalASCNET does not hold any rights over the resource listed here. All rights are retained by the journal listed under publisher and/or the creator(s).

Type

Journal Article

Citation List Month

Backlog

Pages

858-62

Issue

4

Volume

103

Citation

Kushner BH; Kramer K; Modak S; Cheung NK, “Five-day courses of irinotecan as palliative therapy for patients with neuroblastoma,” Pediatric Palliative Care Library, accessed October 16, 2021, https://pedpalascnetlibrary.omeka.net/items/show/13804.

Social Bookmarking